-transparent.png){kind=logo}
Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies. 2015
Liping L Sun, and
Diego Ellerman, and
Mary Mathieu, and
Maria Hristopoulos, and
Xiaocheng Chen, and
Yijin Li, and
Xiaojie Yan, and
Robyn Clark, and
Arthur Reyes, and
Eric Stefanich, and
Elaine Mai, and
Judy Young, and
Clarissa Johnson, and
Mahrukh Huseni, and
Xinhua Wang, and
Yvonne Chen, and
Peiyin Wang, and
Hong Wang, and
Noel Dybdal, and
Yu-Waye Chu, and
Nicholas Chiorazzi, and
Justin M Scheer, and
Teemu Junttila, and
Klara Totpal, and
Mark S Dennis, and
Allen J Ebens
Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA. sun.laura@gene.com.
Bispecific antibodies and antibody fragments in various formats have been explored as a means to recruit cytolytic T cells to kill tumor cells. Encouraging clinical data have been reported with molecules such as the anti-CD19/CD3 bispecific T cell engager (BiTE) blinatumomab. However, the clinical use of many reported T cell-recruiting bispecific modalities is limited by liabilities including unfavorable pharmacokinetics, potential immunogenicity, and manufacturing challenges. We describe a B cell-targeting anti-CD20/CD3 T cell-dependent bispecific antibody (CD20-TDB), which is a full-length, humanized immunoglobulin G1 molecule with near-native antibody architecture constructed using "knobs-into-holes" technology. CD20-TDB is highly active in killing CD20-expressing B cells, including primary patient leukemia and lymphoma cells both in vitro and in vivo. In cynomolgus monkeys, CD20-TDB potently depletes B cells in peripheral blood and lymphoid tissues at a single dose of 1 mg/kg while demonstrating pharmacokinetic properties similar to those of conventional monoclonal antibodies. CD20-TDB also exhibits activity in vitro and in vivo in the presence of competing CD20-targeting antibodies. These data provide rationale for the clinical testing of CD20-TDB for the treatment of CD20-expressing B cell malignancies.
Related Publications
Liping L Sun, and
Diego Ellerman, and
Mary Mathieu, and
Maria Hristopoulos, and
Xiaocheng Chen, and
Yijin Li, and
Xiaojie Yan, and
Robyn Clark, and
Arthur Reyes, and
Eric Stefanich, and
Elaine Mai, and
Judy Young, and
Clarissa Johnson, and
Mahrukh Huseni, and
Xinhua Wang, and
Yvonne Chen, and
Peiyin Wang, and
Hong Wang, and
Noel Dybdal, and
Yu-Waye Chu, and
Nicholas Chiorazzi, and
Justin M Scheer, and
Teemu Junttila, and
Klara Totpal, and
Mark S Dennis, and
Allen J Ebens
May 2016,
Biochemical and biophysical research communications,
Liping L Sun, and
Diego Ellerman, and
Mary Mathieu, and
Maria Hristopoulos, and
Xiaocheng Chen, and
Yijin Li, and
Xiaojie Yan, and
Robyn Clark, and
Arthur Reyes, and
Eric Stefanich, and
Elaine Mai, and
Judy Young, and
Clarissa Johnson, and
Mahrukh Huseni, and
Xinhua Wang, and
Yvonne Chen, and
Peiyin Wang, and
Hong Wang, and
Noel Dybdal, and
Yu-Waye Chu, and
Nicholas Chiorazzi, and
Justin M Scheer, and
Teemu Junttila, and
Klara Totpal, and
Mark S Dennis, and
Allen J Ebens
April 2021,
Molecular cancer therapeutics,
Liping L Sun, and
Diego Ellerman, and
Mary Mathieu, and
Maria Hristopoulos, and
Xiaocheng Chen, and
Yijin Li, and
Xiaojie Yan, and
Robyn Clark, and
Arthur Reyes, and
Eric Stefanich, and
Elaine Mai, and
Judy Young, and
Clarissa Johnson, and
Mahrukh Huseni, and
Xinhua Wang, and
Yvonne Chen, and
Peiyin Wang, and
Hong Wang, and
Noel Dybdal, and
Yu-Waye Chu, and
Nicholas Chiorazzi, and
Justin M Scheer, and
Teemu Junttila, and
Klara Totpal, and
Mark S Dennis, and
Allen J Ebens
May 2018,
Clinical and translational science,
Liping L Sun, and
Diego Ellerman, and
Mary Mathieu, and
Maria Hristopoulos, and
Xiaocheng Chen, and
Yijin Li, and
Xiaojie Yan, and
Robyn Clark, and
Arthur Reyes, and
Eric Stefanich, and
Elaine Mai, and
Judy Young, and
Clarissa Johnson, and
Mahrukh Huseni, and
Xinhua Wang, and
Yvonne Chen, and
Peiyin Wang, and
Hong Wang, and
Noel Dybdal, and
Yu-Waye Chu, and
Nicholas Chiorazzi, and
Justin M Scheer, and
Teemu Junttila, and
Klara Totpal, and
Mark S Dennis, and
Allen J Ebens
December 2017,
Human gene therapy,
Liping L Sun, and
Diego Ellerman, and
Mary Mathieu, and
Maria Hristopoulos, and
Xiaocheng Chen, and
Yijin Li, and
Xiaojie Yan, and
Robyn Clark, and
Arthur Reyes, and
Eric Stefanich, and
Elaine Mai, and
Judy Young, and
Clarissa Johnson, and
Mahrukh Huseni, and
Xinhua Wang, and
Yvonne Chen, and
Peiyin Wang, and
Hong Wang, and
Noel Dybdal, and
Yu-Waye Chu, and
Nicholas Chiorazzi, and
Justin M Scheer, and
Teemu Junttila, and
Klara Totpal, and
Mark S Dennis, and
Allen J Ebens
February 2023,
Cancer immunology, immunotherapy : CII,
Liping L Sun, and
Diego Ellerman, and
Mary Mathieu, and
Maria Hristopoulos, and
Xiaocheng Chen, and
Yijin Li, and
Xiaojie Yan, and
Robyn Clark, and
Arthur Reyes, and
Eric Stefanich, and
Elaine Mai, and
Judy Young, and
Clarissa Johnson, and
Mahrukh Huseni, and
Xinhua Wang, and
Yvonne Chen, and
Peiyin Wang, and
Hong Wang, and
Noel Dybdal, and
Yu-Waye Chu, and
Nicholas Chiorazzi, and
Justin M Scheer, and
Teemu Junttila, and
Klara Totpal, and
Mark S Dennis, and
Allen J Ebens
June 2023,
Investigational new drugs,
Liping L Sun, and
Diego Ellerman, and
Mary Mathieu, and
Maria Hristopoulos, and
Xiaocheng Chen, and
Yijin Li, and
Xiaojie Yan, and
Robyn Clark, and
Arthur Reyes, and
Eric Stefanich, and
Elaine Mai, and
Judy Young, and
Clarissa Johnson, and
Mahrukh Huseni, and
Xinhua Wang, and
Yvonne Chen, and
Peiyin Wang, and
Hong Wang, and
Noel Dybdal, and
Yu-Waye Chu, and
Nicholas Chiorazzi, and
Justin M Scheer, and
Teemu Junttila, and
Klara Totpal, and
Mark S Dennis, and
Allen J Ebens
November 2023,
Cancer immunology, immunotherapy : CII,
Liping L Sun, and
Diego Ellerman, and
Mary Mathieu, and
Maria Hristopoulos, and
Xiaocheng Chen, and
Yijin Li, and
Xiaojie Yan, and
Robyn Clark, and
Arthur Reyes, and
Eric Stefanich, and
Elaine Mai, and
Judy Young, and
Clarissa Johnson, and
Mahrukh Huseni, and
Xinhua Wang, and
Yvonne Chen, and
Peiyin Wang, and
Hong Wang, and
Noel Dybdal, and
Yu-Waye Chu, and
Nicholas Chiorazzi, and
Justin M Scheer, and
Teemu Junttila, and
Klara Totpal, and
Mark S Dennis, and
Allen J Ebens
February 2019,
Methods (San Diego, Calif.),
Liping L Sun, and
Diego Ellerman, and
Mary Mathieu, and
Maria Hristopoulos, and
Xiaocheng Chen, and
Yijin Li, and
Xiaojie Yan, and
Robyn Clark, and
Arthur Reyes, and
Eric Stefanich, and
Elaine Mai, and
Judy Young, and
Clarissa Johnson, and
Mahrukh Huseni, and
Xinhua Wang, and
Yvonne Chen, and
Peiyin Wang, and
Hong Wang, and
Noel Dybdal, and
Yu-Waye Chu, and
Nicholas Chiorazzi, and
Justin M Scheer, and
Teemu Junttila, and
Klara Totpal, and
Mark S Dennis, and
Allen J Ebens
September 2019,
Molecular cancer therapeutics,
Liping L Sun, and
Diego Ellerman, and
Mary Mathieu, and
Maria Hristopoulos, and
Xiaocheng Chen, and
Yijin Li, and
Xiaojie Yan, and
Robyn Clark, and
Arthur Reyes, and
Eric Stefanich, and
Elaine Mai, and
Judy Young, and
Clarissa Johnson, and
Mahrukh Huseni, and
Xinhua Wang, and
Yvonne Chen, and
Peiyin Wang, and
Hong Wang, and
Noel Dybdal, and
Yu-Waye Chu, and
Nicholas Chiorazzi, and
Justin M Scheer, and
Teemu Junttila, and
Klara Totpal, and
Mark S Dennis, and
Allen J Ebens
July 2010,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
